Rosetta Capital
Overview
Rosetta is a UK-based venture capital firm specializing in the life sciences and medical device sectors . Their investment approach is global, building leading healthcare companies and groundbreaking technologies with the potential to enhance human lives . Their primary focus is direct secondary transactions, offering adaptable liquidity solutions to investors and corporations .
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Mission Therapeutics | Oct 2025 | Series D Extension | Lead |
| Dilafor | Sep 2016 | VC Round | Lead |
| PMD Device Solutions AB | Jul 2017 | IPO | Co-investor |
| Carrick Therapeutics | Dec 2022 | Series C | - |
| Light Chain Bioscience | Feb 2014 | Series B | Lead |
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is Rosetta Capital based?
Rosetta Capital is headquartered in Haddenham, England, United Kingdom.
When was Rosetta Capital founded?
Rosetta Capital was founded in 2001.
How many portfolio companies does Rosetta Capital have?
Rosetta Capital has 7 portfolio companies in Caplight's dataset.
What are some companies in Rosetta Capital's portfolio?
Portfolio companies visible on Caplight include Mission Therapeutics, Dilafor, PMD Device Solutions AB, Carrick Therapeutics, Light Chain Bioscience.
What was Rosetta Capital's most recent investment shown here?
Rosetta Capital's most recent investment in this portfolio sample was in Mission Therapeutics in 2025.
What sectors does Rosetta Capital focus on?
Rosetta Capital focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Frontier & Industrial Tech, Enterprise Software, Frontier & Industrial Tech.
What company stages does Rosetta Capital focus on?
Rosetta Capital typically invests at the Late stage.
What is Rosetta Capital's AUM?
Rosetta Capital's assets under management are estimated between $0.0 and $50.0M.